<DOC>
	<DOCNO>NCT01083186</DOCNO>
	<brief_summary>The purpose study obtain data use Zemplar ( paricalcitol ) capsule real-life clinical practice predialysis patient chronic kidney disease ( CKD ) secondary hyperparathyroidism .</brief_summary>
	<brief_title>Paricalcitol Oral Therapy Predialysis CKD Patients . The Greek Experience</brief_title>
	<detailed_description>This single arm , open , multicenter , non-interventional , post marketing observational study , conduct 24 site Greece , normal clinical practice per locally approve Summary Product Characteristics ( SmPC ) study medication ( oral paricalcitol ) . Eligible patient follow 12-month period enrollment . All study activity consistent European Union ( EU ) directive 2001/20/EC section non-interventional study . In study , paricalcitol prescribe on-label basis everyday set observe drug action distinct geography ( Greece &gt; 250 days/year sunny day ) well significant subpopulation ( Chronic Kidney Disease [ CKD ] stag 3-5 transplanted patient ) . Dose tolerability , treatment effect , well maintenance result register 12-month period order obtain experience long term use paricalcitol capsule . Furthermore , center additional blood parameter examine part clinical routine , record analyze .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Patients secondary hyperparathyroidism presence chronic kidney disease stage 3 , 4 5 treat Zemplar ( paricalcitol ) oral least 1 month prior study enrollment Male female ( pregnant planning pregnant next 12 month ) patient &gt; 18 year age Signed informed consent subject Hypertensive diabetic subject must optimal steady medication regimen 30 day Contraindications list Summary Product Characteristics Zemplar capsule apply ( Appendix I II ) Parathormone value &gt; 1000 pg/mL ( sign tertiary hyperparathyroidism ) Treatment Vitamin D within last 1 month prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Chronic Kidney Failure</keyword>
</DOC>